Edition:
United Kingdom

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.87USD
23 Feb 2018
Change (% chg)

$0.01 (+0.35%)
Prev Close
$2.86
Open
$2.88
Day's High
$2.91
Day's Low
$2.81
Volume
245,362
Avg. Vol
316,968
52-wk High
$4.24
52-wk Low
$0.50

Select another date:

Fri, Feb 16 2018

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs

* AVEO ONCOLOGY ANNOUNCES CLINICAL UPDATES TO TIVOZANIB AND FICLATUZUMAB PROGRAMS

BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln

* AVEO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: [http://bit.ly/2Bzw8T1] Further company coverage:

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

Select another date: